help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellezza, I.
Right arrow Articles by Culig, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellezza, I.
Right arrow Articles by Culig, Z.
(American Journal of Pathology. 2006;169:2199-2208.)
© 2006 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.060171

Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer

Ilaria Bellezza*{dagger}, Hannes Neuwirt*, Constanze Nemes{ddagger}, Ilaria T. Cavarretta*, Martin Puhr*, Hannes Steiner*, Alba Minelli{dagger}, Georg Bartsch*, Felix Offner{ddagger}, Alfred Hobisch§, Wolfgang Doppler and Zoran Culig*

From the Department of Urology* and the Division of Medical Biochemistry, Innsbruck Medical University, Innsbruck, Austria; the Departments of Pathology{ddagger} and Urology,§ General Hospital Feldkirch, Feldkirch, Austria; and the Department of Experimental Medicine and Biochemical Sciences,{dagger} University of Perugia, Perugia, Italy

Interleukin-6, levels of which are elevated in prostate cancer, activates different signal transduction pathways including that of Janus kinases/signal transducer and activator of transcription (STAT)3. However, phosphorylation of STAT3 has been reported to be associated with either stimulatory or inhibitory effects on cellular proliferation. To better understand the mechanisms of STAT3 regulation in benign and malignant prostate, we have investigated the role of suppressor of cytokine signaling (SOCS)-3. Cell lines that did not express phosphorylated STAT3 were found to be SOCS-3-positive. SOCS-3 was re-expressed in LNCaP cells after treatment with a demethylating agent. SOCS-3 immunohistochemistry revealed a negative or weak reaction in benign areas, whereas its expression was detected in tumor tissue. To investigate the involvement of SOCS-3 in regulation of cellular events, we incubated cancer cells with a cAMP derivative. This treatment yielded higher SOCS-3 levels, reduced [3H]thymidine incorporation, and increased percentage of apoptotic cells. However, down-regulation of SOCS-3 by a short interfering RNA approach resulted in inhibition of proliferation and an increased apoptotic rate. Collectively, our results show that SOCS-3 antagonizes regulation of cellular events by cAMP and is expressed in human prostate cancer.




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
H. Neuwirt, M. Puhr, I. T Cavarretta, M. Mitterberger, A. Hobisch, and Z. Culig
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion
Endocr. Relat. Cancer, December 1, 2007; 14(4): 1007 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Qin, K. L. Roberts, S. A. Niyongere, Y. Cong, C. O. Elson, and E. N. Benveniste
Molecular Mechanism of Lipopolysaccharide-Induced SOCS-3 Gene Expression in Macrophages and Microglia
J. Immunol., November 1, 2007; 179(9): 5966 - 5976.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology.